tradingview.com
Cure8 news brief
Why This Matters
Regulatory approvals and trial activity for upadacitinib (Rinvoq) affect availability and prescribing patterns for immunomodulatory treatment options used across autoimmune and inflammatory diseases, including IBD.
Expansion of indications and ongoing pediatric studies may influence future treatment choices and access for patients.
Who Should Pay Attention
Patients with IBD (including those on or considering advanced therapies), pediatric IBD caregivers, gastroenterologists and rheumatologists, and researchers following JAK inhibitor development and regulatory changes.
Study Snapshot
Story typeBusiness news
Evidence typeRegulatory update
Source depthFull source text
What To Know
The European Commission approved AbbVie’s Rinvoq (upadacitinib) for active polyarticular juvenile idiopathic arthritis (pJIA) in patients aged two years and older, including use as monotherapy or with methotrexate.
The article notes Rinvoq is already approved in the EU for multiple chronic inflammatory conditions, explicitly listing ulcerative colitis and Crohn’s disease, and that the drug is being studied in pediatric and other inflammatory indications. The piece also reports a separate AbbVie collaboration with Iambic to apply AI-driven drug discovery.
Keep In Mind
This is a business/finance report summarizing an EC regulatory approval and company pipeline activity. The approval described is for juvenile idiopathic arthritis (pJIA); references to other indications (including ulcerative colitis and Crohn’s disease) reflect existing or investigational uses noted by the company, not new approvals for IBD in this article.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationtradingview.com
Indexed viaGoogle News
Source typeWeb article
PublishedSep 22, 2026, 5:31 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
AbbVie's Immunology Franchise: From Skyrizi & Rinvoq to What's Next - TradingView
This article explains why two widely used IBD drugs from AbbVie (Skyrizi and Rinvoq) are central to the company’s growth and describes ongoing development efforts that could expand treatment options and indications in...
AbbVie Data Underscores Immunology Growth Potential With SKYRIZI And RINVOQ
New long-term and real-world data on SKYRIZI and RINVOQ were presented at DDW, which may influence how clinicians, payers, and patients view these options for Crohn's disease and ulcerative colitis.
How Much Did Immunology Drugs Contribute to AbbVie's Q2 Performance? - TradingView
Growth and new approvals for Skyrizi and Rinvoq may increase treatment options and influence which drugs gastroenterologists prescribe for Crohn’s disease and ulcerative colitis. Changes in approvals, dosing options, and...